西妥昔单抗联合FOLFIRI方案治疗结直肠癌疗效及对血清ESM1、SRPX2、VEGF水平的影响  

Efficacy of cetuximab combined with FOLFIRI regimen in treatment of colorectal cancer and its effects on levels of serum ESM1,SRPX2 and VEGF

作　　者：常伟纳 王璇 楚盼盼 马凯月 CHANG Weina;WANG Xuan;CHU Panpan;MA Kaiyue(Department of Pharmacy,Kaifeng People's Hospital,Henan 475000,China)

机构地区：[1]河南省开封市人民医院药剂科,475000

出　　处：《淮海医药》2021年第6期586-590,共5页Journal of Huaihai Medicine

摘　　要：目的:探讨西妥昔单抗联合FOLFIRI方案治疗结直肠癌的疗效及对血清内皮细胞特异性分子-1(ESM1)、含sushi重复蛋白X连锁2(SRPX2)、血管内皮生长因子(VEGF)水平的影响。方法:回顾性分析某院接受治疗的162例经病理学确诊的结直肠癌患者的临床资料,按照治疗方法的不同分为观察组(n=88)与对照组(n=74)。对照组予以单纯FOLFIRI化疗方案(伊立替康+亚叶酸钙+5-氟尿嘧啶)治疗,观察组加以西妥昔单抗联合治疗,均持续治疗4~6个周期后按实体瘤疗效判定标准评估2组患者近期临床疗效,并记录其治疗前后的免疫功能(CD^(3+)、CD^(4+)、CD^(8+)、CD^(4+)/CD^(8+))、血清肿瘤标志物〔ESM1、SRPX2、VEGF、CEA、糖类抗原199(CA199)〕变化、毒副反应发生及生存情况。结果:观察组总有效率、总获益率明显高于对照组(P<0.05);治疗后,观察组患者CD^(3+)、CD^(4+)及CD^(4+)/CD^(8+)水平高于治疗前及同期对照组,CD^(8+)、ESM1、SRPX2、VEGF、CEA、CA199水平低于治疗前及同期对照组(P<0.05);观察组皮疹过敏及骨髓抑制发生率、1年生存率明显高于对照组(P<0.05),2组患者恶心呕吐、肝功能损害、肾功能损害发生率、6个月生存率比较差异无统计学意义(P>0.05)。结论:西妥昔单抗联合FOLFIRI方案治疗结直肠癌效果理想,可有效降低血清ESM1、SRPX2、VEGF水平,提高免疫功能,并有利于短期生存率的提高,值得推广。Objective:To explore the efficacy of cetuximab combined with FOLFIRI regimen in the treatment of colorectal cancer and its effects on levels of serum endothelial cell specific molecule-1(ESM1),sushi repeat-containing protein x-linked 2(SRPX2)and vascular endothelial growth factor(VEGF).Methods:Clinical data of 162 patients with colorectal cancer confirmed by pathology were retrospectively analyzed.According to the treatment methods,the patients were divided into an observation group(n=88)and a control group(n=74).The control group was treated with simple FOLFIRI chemotherapy regimen(irinotecan+leucovorin+5-fluorouracil),and the regimen of the observation group was,on the basis of the above,combined with cetuximab.After 4 to 6 cycles of continuous treatment,the short-term clinical efficacy was evaluated in the two groups according to the criteria of solid tumor efficacy,and the immune function(CD^(3+),CD^(4+),CD^(8+),CD^(4+)/CD^(8+)),serum tumor markers(ESM1,SRPX2,VEGF,CEA,CA199),occurrence of toxic and side effects and survival status were recorded before and after treatment.Results:The total effective rate and the total benefit rate of the observation group were significantly higher than those of the control group(P<0.05).After treatment,the levels of CD^(3+),CD^(4+)and CD4+/CD^(8+)in the observation group were significantly higher than those before treatment,and were significantly higher than those in the control group;the levels of CD^(8+),ESM1,SRPX2,VEGF,CEA,and CA199 were significantly lower than those before treatment,and were significantly lower than those in the control group(P<0.05).The incidence rates of allergic skin rash and myelosuppression of the observation group were significantly higher than those of the control group(P<0.05),but there were no statistically significant differences in the incidence rates of nausea and vomiting,liver function damage and renal function damage between the two groups(P>0.05).The 1-year survival rate of the observation group was significantly higher than that of the co

关 键 词：结直肠肿瘤 西妥昔单抗 FOLFIRI方案 内皮细胞特异性分子-1 含sushi重复蛋白X连锁2 血管内皮生长因子 

分 类 号：R735.3[医药卫生—肿瘤]